AKT1 and prostate carcinoma: Unlike inhibition of androgen receptor and heat shock proteins in prostate cancer cells or targeting the phosphoinositide 3‐kinase/Akt/mechanistic target of rapamycin pathway in lung adenocarcinoma cells [5], CBT enhances the antitumor pathway‐p53 signaling pathway in colorectal cancer cells.